Rajavelu Esther 4

What Happened
Esther Rajavelu — listed as Chief Executive Officer (also noted as Chief Financial Officer and Chief Business Officer) — reported two sales on 2026-02-06 disposing of a total 87,917 shares of Spero Therapeutics (SPRO). The sales were: 37,101 shares at $2.36 each for $87,558, and 50,816 shares at $2.36 each for $119,926, for combined proceeds of about $207,484. These were sales (S) and, per the filing footnote, were automatic "sell-to-cover" transactions to satisfy tax withholding on vested RSUs rather than discretionary trades.

Key Details

• Transaction dates and prices: 2026-02-06 — 37,101 shares @ $2.36; 50,816 shares @ $2.36.
• Total proceeds: ~$207,484.
• Footnote: Sale was to cover tax withholding on RSU vesting (automatic "sell-to-cover"); not a discretionary sale.
• Shares owned after transaction: Not specified in the filing.
• Filing date: 2026-02-09; the Form 4 was filed promptly following the 2026-02-06 transactions (no late filing indicated).

Context
Sell-to-cover transactions are common when restricted stock units vest and the holder owes taxes; they typically do not signal a deliberate decision to reduce an insider’s exposure. For retail investors, outright purchases by insiders tend to be more informative about confidence than routine tax-related sales.